Obesity Management in Primary Care

<p>Obesity affects approximately 42% of adults in the US. Multiple strategies are available to treat obesity, including behavior therapies, GLP-1 receptor agonists, and bariatric surgery. Therapies vary in effectiveness and risks. JAMA Deputy Editor Mary McGrae McDermott, MD, discusses evidence-based obesity treatment with Melanie Jay, MD, MS, New York University Grossman School of Medicine.<br /> <br /> <strong>Related Content:</strong></p> <ul> <li><a class="related-article" href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.19897?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">Obesity Management in Adults</a></li> <li><a class="related-article" href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.16620?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">As Semaglutide’s Popularity Soars, Rare but Serious Adverse Effects Are Emerging</a></li> <li><a class="related-article" href= "https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.24539?utm_source=podcast_platforms&utm_medium=referral&utm_campaign=related_article_links" target="_blank" rel="noopener">FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management</a></li> </ul>